Clinical Trials Logo
  1. Home
  2. Non-melanoma Skin Cancer
  3. NCT05257486

Post-market Multi-Center RETRO-Prospective Study to Assess Long-term Clinical Outcomes NMSC Patients Treated With eBx

Non-melanoma Skin Cancer Clinical Trial

Official title:
A Post-market Multi-Center Retrospective-Prospective Study to Assess Long-term Clinical Outcomes of Non-melanoma Skin Cancer Patients Treated With eBx

Clinical Trial Summary

The purpose of this retrospective-prospective study is to evaluate lesions after treatment for BCC or SCC NMSC in order to gain a better understanding of the durability of the treatment, and risk of late toxicities for this patient population.

Clinical Trial Description

This is a retrospective-prospective study design. The study is post-market, on-label observational study for the treatment of NMSC. Patients who completed treatment at least five years from the last treatment will be identified and existing data as required by this protocol in the patient's record will be collected in addition to conducting office visits or telehealth visits (video) for long-term follow-up. The study will include: Identifying patients, retrospectively, who completed treatment a minimum of five years from the last treatment. The history and demographic data will be collected from up to 300 subjects previously treated with eBx for the treatment of NMSC. Patients will have an office visit or telehealth visit in order for the investigators to assess the lesion site, document absence of recurrence, treatment for recurrence (if applicable), and long-term toxicities at the time of the prospective visit. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05257486
Study type Observational
Source Xoft, Inc.
Contact
Status Enrolling by invitation
Phase
Start date March 9, 2022
Completion date March 1, 2023
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04103658 - NIR and Skin Cancer Margins N/A
Completed NCT01053819 - Can We Miss Pigmented Lesions in Psoriasis Patients? Phase 4
Recruiting NCT03767348 - Study of RP1 Monotherapy and RP1 in Combination With Nivolumab Phase 2
Recruiting NCT05429866 - Immunological Variables Associated to ICI Toxicity in Cancer Patients Phase 2
Active, not recruiting NCT02636569 - Topical Chemoprevention of Skin Cancer Biomarkers Phase 2
Completed NCT02760160 - Dietary Prevention of Photodamage in Skin With Grapes N/A
Completed NCT02780934 - Comparing Pressure Versus Simple Adhesive Dressing After Mohs Reconstruction N/A
Completed NCT02872909 - Randomized Comparison of Low and Conventional Irradiance PDT for Skin Cancer N/A
Withdrawn NCT03327064 - A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer Phase 1/Phase 2
Completed NCT00342407 - The Incidence of Breast and Other Cancers Among Female Flight Attendants
Terminated NCT04410874 - Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer Phase 1/Phase 2
Completed NCT03693937 - A Retrospective Evaluation of Superficial Radiation Therapy (SRT) and Non-Melanoma Skin Cancer (NMSC)
Completed NCT04334824 - Hydrochlorothiazide and Risk of Skin Cancer
Recruiting NCT05878288 - Deep sequencIng in Cutaneous Squamous CEll caRciNomas Phase 2
Completed NCT01359735 - Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients Phase 2
Terminated NCT04348916 - Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors Phase 1
Withdrawn NCT03757663 - UV Dosimetry Feedback in NMSC Patients N/A
Completed NCT04116983 - DERM NMSC Validation Study
Active, not recruiting NCT06227416 - Skin Tumor Biomarkers by Mass Spectrometry Imaging N/A
Recruiting NCT05932511 - Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer Early Phase 1